2.43
-0.435(-15.21%)
Currency In USD
| Previous Close | 2.86 |
| Open | 2.88 |
| Day High | 2.97 |
| Day Low | 2.4 |
| 52-Week High | 13.07 |
| 52-Week Low | 1.29 |
| Volume | 3.71M |
| Average Volume | 1.82M |
| Market Cap | 91.11M |
| PE | -0.69 |
| EPS | -3.54 |
| Moving Average 50 Days | 1.87 |
| Moving Average 200 Days | 5.18 |
| Change | -0.44 |
If you invested $1000 in Biomea Fusion, Inc. (BMEA) since IPO date, it would be worth $130.38 as of June 05, 2025 at a share price of $2.425. Whereas If you bought $1000 worth of Biomea Fusion, Inc. (BMEA) shares 3 years ago, it would be worth $450.74 as of June 05, 2025 at a share price of $2.425.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biomea Fusion’s BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia
GlobeNewswire Inc.
May 14, 2025 8:05 PM GMT
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that preliminary clinical data from the Phase I COVALENT-103 trial of BMF
Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights
GlobeNewswire Inc.
May 05, 2025 8:05 PM GMT
Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients that are currently uncontrolled o
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Apr 01, 2025 8:01 PM GMT
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on March 23, 2025, the compensation committee of